|
Vaccine Detail
Pfs48/45 in Matrix-M |
Vaccine Information |
- Vaccine Name: Pfs48/45 in Matrix-M
- Target Pathogen: Plasmodium spp.
- Target Disease: Malaria
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: Pfs48/45 (Minassian et al., 2022): plays an important role in the fertilization of plasmodium: males lacking Pfs48/45 show severely reduced fertility and are incapable of adhering to and penetrating female gametes. (Theisen et al., 2017)
- Pfs48/45
gene engineering:
- Type: Recombinant protein preparation
- Description: Pfs48/45 and the 10 C and 6 C fusion proteins. The secondary structure prediction of Pfs48/45 have assigned 2 loops in domain II between amino acid residues 190–210 and 239–259, and in domain III between the residues 302–327 and 357–397. Epitope I is located between residues 295 and 418. (Theisen et al., 2017)
- Detailed Gene Information: Click Here.
- Immunization Route: Intramuscular injection (i.m.)
- Description: Transmission Blocking Vaccine: induce antibodies that taken up by the mosquito and subsequently prevent development of parasites in the mosquito midgut (Theisen et al., 2017)
|
Host Response |
Human Response
- Host Strain: adults living in UK(Minassian et al., 2022)
- Vaccination Protocol: Non-randomized, phase Ia trial, not strated.
Participants will be separated into three different groups with 8-10 participants in each group: 1) low dose: three doses of 10 µg Pfs48/45 in 50 µg Matrix-M on days 0, 28 and 56; 2) standard dose: three doses of 50 µg Pfs48/45 in 50 µg Matrix-M on days 0, 28 and 56; and 3) two doses of 50 µg Pfs48/45 in 50 µg Matrix-M on days 0 and 28, followed by one dose of 10 µg Pfs48/45 in 50 µg Matrix-M on day 56. (Minassian et al., 2022)
|
References |
Minassian et al., 2022: A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK [https://clinicaltrials.gov/ct2/show/NCT05400746?term=vaccine&cond=Plasmodium&draw=8&rank=70]
Theisen et al., 2017: Theisen M, Jore MM, Sauerwein R. Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine. Expert review of vaccines. 2017; 16(4); 329-336. [PubMed: 28043178].
|
|